Atlas Trials

Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)

Clinical trial NCT06832904 · RECRUITING

Trial details

NCT number
NCT06832904
Sponsor
First Affiliated Hospital of Zhejiang University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-positive Breast CancerNeoadjuvant TherapyPyrotinib
Start date
2024-12-03
Primary completion
2028-01-01
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.